var quiz = [
  {
    q: `The term “castration-resistant disease” has replaced the older classification of “hormone-resistant disease” used to define all patients who demonstrate evidence of disease progression after initial androgen deprivation treatment because:`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->androgen deprivation treatment focusing on medical/surgical castration is the initial systemic approach for patients with metastatic prostate cancer.`,
      `<!--b. -->in patients with castration-resistant disease, responses to subsequent androgen receptor (AR)-targeted treatments continue to show a benefit.`,
      `<!--c. -->current data indicate that the AR continues to play a major role in the control of prostate cancer growth even when serum levels of testosterone are in the castrate range (&lt;50 ng/dL).`,
      `<!--d. -->castration resistance does not equal hormone resistance.`,
      `<!--e. --><b>all of the above adequately describe the castration-resistant state.</b>`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [4],
    ansText: ``,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
  },
  {
    q: `Patients eventually stop benefiting from primary and secondary hormonal treatments and become refractory. Which of the following statement(s) INCORRECTLY defines the “castration-resistant” paradigm?`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->Careful clinical monitoring of patients in clinical practice, including regular physical exams and sequential assessments of radiologic parameters and serum prostate-specific antigen (PSA) levels, facilitates early identification of patients who are becoming resistant to secondary hormonal manipulations.`,
      `<!--b. -->The definition of castration resistance is based on well-defined clinical and pathologic criteria such as Gleason score and extent of disease.`,
      `<!--c. -->Determination of castration resistance requires clinical evidence of PSA or disease progression to primary and secondary hormonal manipulations.`,
      `<!--d. -->The vast majority of patients treated with endocrine manipulations will develop evidence of disease progression and eventually require chemotherapy.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [1],
    ansText: ``,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
  },
  {
    q: `Docetaxel remains the standard first-line chemotherapy treatment for patients with metastatic castration-resistant prostate cancer considered candidates for this modality. Which of the following statement(s) is NOT true?`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->Docetaxel infusion every 3 weeks (for as many as 10 cycles) given in conjunction with daily oral prednisone is the standard schedule that has been shown to prolong survival and improve quality of life compared with mitoxantrone.`,
      `<!--b. -->Significant clinical benefits are seen in patients regardless of their age, functional status, and presence or absence of pain.`,
      `<!--c. -->Patients with metastatic castration-resistant disease who have favorable functional status (fully ambulatory, asymptomatic), no visceral involvement, and normal hemoglobin and serum lactate dehydrogenase (LDH) have survival outcomes using docetaxel that frequently exceed 2 years.`,
      `<!--d. -->Frequent toxicities associated with docetaxel treatment include fatigue, myelosuppression, neuropathy, lacrimation, and nail changes, among others. Routine clinical and laboratory evaluation before each cycle is indicated.`,
      `<!--e. -->Patients demonstrating rising serum PSAs during the first three to four cycles of treatment should probably be taken off treatment because it is not effective.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [4],
    ansText: ``,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `Cabazitaxel is another taxane approved for metastatic castration-resistant prostate cancer. In preclinical studies that used cancer cell lines and mouse xenograft models, cabazitaxel was shown to be active in docetaxel-sensitive tumors, as well as those with primary or acquired docetaxel resistance. Which of the following statements adequately describes the clinical experience with this compound?`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->Cabazitaxel was shown to prolong survival compared with mitoxantrone in patients previously treated with docetaxel.`,
      `<!--b. -->The toxicity pattern of cabazitaxel suggests a lower incidence of neuropathy, fatigue, lacrimation, and nail changes but has a higher incidence of neutropenic fever and diarrhea compared with docetaxel.`,
      `<!--c. -->Data on the TROPIC trial suggest that patients who fail to respond or develop early evidence of disease progression after docetaxel may benefit from cabazitaxel.`,
      `<!--d. -->Patients demonstrating disease progression after docetaxel can still survive longer than 12 months with cabazitaxel treatment.`,
      `<!--e. -->All of the above are correct.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [4],
    ansText: ``,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `After initial gonadal suppression, AR signaling is upregulated in castration-resistant disease and continues to play a major role in tumor growth. Which of the following statement(s) adequately describes AR-targeted treatments?`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->CYP17 inhibitors target androgen synthesis both of adrenal and intracrine source and yield significant benefit in patients treated with first-line gonadal suppression who subsequently develop evidence of disease progression. This effect has been shown in patients with or without previous treatment with docetaxel.`,
      `<!--b. -->The side effects with abiraterone acetate include a mineralocorticoid excess state (efficiently prevented by a concomitant administration of prednisone), fatigue, abnormal liver function tests, possible cardiac toxicity, and potential drug interactions.`,
      `<!--c. -->Enzalutamide is a nonsteroidal antiandrogen that differs from the first-generation compounds (flutamide, bicalutamide, and nilutamide) based on a greater AR affinity, AR nuclear translocation, and DNA binding. Most patients with castration-resistant disease benefit from treatment, which was shown to be significantly superior to placebo in prospective randomized trials.`,
      `<!--d. -->The benefits from CYP17 inhibitors (abiraterone) and AR antagonists (enzalutamide) are most likely more pronounced in patients who have not received prior docetaxel treatment.`,
      `<!--e. -->All of the above are correct.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [4],
    ansText: ``,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `Which of the following statements is correct regarding patients with widely metastatic prostate cancer who present with back pain?`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->Administration of narcotic analgesics is the appropriate management, and if pain management becomes more challenging, patients should be referred to hospice.`,
      `<!--b. -->All patients with known bone metastasis should be carefully assessed clinically for the possibility of epidural cord or nerve root compression. Administration of high-dose dexamethasone and early magnetic resonance imaging (MRI) should be used, and more definitive treatment with radiation or neurosurgical decompression should be considered.`,
      `<!--c. -->Patients with back pain and stable skeletal radiographs should be treated with narcotic analgesics and corticosteroids. If improvement occurs, no further evaluation is necessary.`,
      `<!--d. -->If the PSA is not rising and the workup with a bone scan and computed tomography (CT) scans reveal stable disease, it can be assumed that cord compression or other complex neurologic involvement is unlikely.`,
      `<!--e. -->Most current systemic treatments are effective for managing extensive bone metastasis even if there is evidence of nerve root or cord compression.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [1],
    ansText: ``,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `A small proportion of patients with advanced-stage disease develop a syndrome of rapid and dramatic development of severe symptoms (pain, obstruction, weight loss) and clinical evidence of rapidly growing disease with soft tissue and organ involvement. In these patients, typically serum PSA levels are either below detectable levels or grossly disproportionate to the other extent of disease parameters. Which statement is correct regarding this rare event in castration-resistant prostate cancer?`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->These patients usually benefit from hormonal therapy including all AR-targeted compounds.`,
      `<!--b. -->Serum PSA is low or undetectable, and the PSA stains in tumor biopsies are usually negative. These tumors do not express AR.`,
      `<!--c. -->A small proportion of patients demonstrate evidence of a rapidly progressing disease predominantly involving visceral sites, with low or no PSA expression. Biopsy is indicated because it will affect treatment decisions.`,
      `<!--d. -->Patients with this clinical syndrome often demonstrate anaplastic tumors at biopsy, some with small-cell features, and most stain positive for neuroendocrine markers. Platinum-based chemotherapy has been shown to offer some benefits for patients with the small-cell variety, whereas those with anaplastic tumors that are not of the small-cell subtype should be treated with taxane-based chemotherapy.`,
      `<!--e. -->All statements are correct except a.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [4],
    ansText: ``,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `The radiopharmaceutical radium-223 was approved for the treatment of patients with metastatic castration-resistant disease. Which statement regarding 223Ra is FALSE?`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->Radium-223 is an α-emitting radiopharmaceutical that has recently shown to be associated with a survival advantage compared to symptomatic/palliative care.`,
      `<!--b. -->α particles are approximately 7000 times heavier than β particles, and as few as one or two hits can be sufficient to cause cell death, in comparison with hundreds or thousands of hits required from β particles. In addition, α particles have a very short path length (&lt;100 μm), which may spare surrounding healthy bone marrow, thereby limiting hematologic toxicities.`,
      `<!--c. -->Radium-223 infusion has shown a very favorable toxicity spectrum with low hematologic toxicity rates.`,
      `<!--d. -->It is indicated for patients with bone metastasis, hemoglobin greater than 10 g/L, and lymph-node metastasis smaller than 3 cm.`,
      `<!--e. -->It was approved only for patients who have received prior docetaxel treatment.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [4],
    ansText: ``,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `Sipuleucel-T is a personalized vaccine derived from autologous CD54 + dendritic cells, the major class of antigen-presenting cells, which are apheresed from individuals and processed with a recombinant fusion protein made up of prostatic acid phosphatase (PAP) and granulocyte-macrophage–colony-stimulating factor (GM-CSF). Which statement is TRUE regarding this treatment?`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->Sipuleucel-T is approved for all patients with castration-resistant disease as long as they are symptomatic.`,
      `<!--b. -->Sipuleucel-T treatment results in PSA declines and prolongation of progression-free survival but no survival improvements.`,
      `<!--c. -->Sipuleucel-T should be offered to patients with no evidence of metastasis as long as their disease is castration resistant.`,
      `<!--d. -->Sipuleucel-T is a treatment option for patients with minimally or asymptomatic metastatic prostate cancer. Treatment is generally very safe. There is no evidence that sipuleucel-T treatment causes symptomatic relief, any clinically meaningful PSA declines, or delay in disease progression. The drug was approved based on a survival benefit compared with placebo.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [3],
    ansText: ``,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
  },
  {
    q: `The nonmetastatic castrate-resistant prostate cancer state, also known as M0 CRPC, is an evolving disease entity with its own therapeutic considerations. Which of these statements about the nonmetastatic CRPC state is FALSE?`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->This clinical state is defined by a rising PSA level, castrate testosterone levels (&lt;50 ng/dL), and a lack of radiographic metastases on conventional CT/MRI and nuclear medicine bone scans.`,
      `<!--b. -->Apalutamide was the first drug to be U.S. Food and Drug Administration (FDA) approved specifically for men with nonmetastatic (M0) CRPC.`,
      `<!--c. -->Enzalutamide is FDA approved for all patients with CRPC, including both those with metastatic (M1) CRPC and nonmetastatic (M0) CRPC.`,
      `<!--d. -->Abiraterone acetate has also recently received FDA approval for use in men with M0 CRPC, as well as its prior approval for M1 mCRPC.`,
      `<!--e. -->All of these statements are true, and none are false.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [3],
    ansText: `Rationale: <b>The only agents with regulatory approval for M0 CRPC are apalutamide and enzalutamide.</b>`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
];
